Br Med J. 1971 Mar 20;1(5750):640-1.
141 received cyclophosphamide and 133 melphalan. The trial began on 1 October 1964 and the intake of patients continued until 31 July 1968. The statistical analysis includes follow-up of the surviving patients to 31 May 1970.The most important single factor affecting the prognosis was the blood urea concentration at presentation. The median survival of the 125 patients whose blood urea concentration was less than 40 mg/100 ml was 33 months, compared with 20 months for the 96 patients whose blood urea concentration was 40-79 mg/100 ml and two months for the 55 patients whose blood urea concentration was 80 mg/100 ml or more.The median survival periods of the 114 patients in the cyclophosphamide group and of the 105 in the melphalan group whose blood urea concentration at presentation was less than 80 mg/100 ml were 27 and 23 months respectively. The difference is not statistically significant.
141人接受环磷酰胺治疗，133人接受美法仑治疗。试验于1964年10月1日开始，患者入组持续至1968年7月31日。统计分析包括对存活患者随访至1970年5月31日。影响预后的最重要单一因素是就诊时的血尿素浓度。血尿素浓度低于40mg/100ml的125例患者的中位生存期为33个月，而血尿素浓度为40 - 79mg/100ml的96例患者为20个月，血尿素浓度为80mg/100ml或更高的55例患者为2个月。就诊时血尿素浓度低于80mg/100ml的环磷酰胺组114例患者和美法仑组105例患者的中位生存期分别为27个月和23个月。差异无统计学意义。
